BioAtla, Inc.
BCAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $11,000 | $0 | $0 | $250 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $925 | $1,221 | $1,199 | $0 |
| Gross Profit | $10,075 | -$1,221 | -$1,199 | $250 |
| % Margin | 91.6% | – | – | 100% |
| R&D Expenses | $63,095 | $103,731 | $79,347 | $58,274 |
| G&A Expenses | $21,848 | $25,956 | $28,793 | $38,416 |
| SG&A Expenses | $21,848 | $25,956 | $28,793 | $38,416 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$925 | -$1,221 | -$1,199 | $0 |
| Operating Expenses | $84,018 | $128,466 | $106,941 | $96,690 |
| Operating Income | -$73,943 | -$129,687 | -$108,140 | -$96,440 |
| % Margin | -672.2% | – | – | -38,576% |
| Other Income/Exp. Net | $4,167 | $6,225 | $1,658 | $1,038 |
| Pre-Tax Income | -$69,776 | -$123,462 | -$106,482 | -$95,402 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$69,776 | -$123,462 | -$105,283 | -$95,402 |
| % Margin | -634.3% | – | – | -38,160.8% |
| EPS | -1.44 | -2.58 | -2.74 | -2.76 |
| % Growth | 44.2% | 5.8% | 0.7% | – |
| EPS Diluted | -1.44 | -2.58 | -2.74 | -2.76 |
| Weighted Avg Shares Out | 48,573 | 47,778 | 38,927 | 34,561 |
| Weighted Avg Shares Out Dil | 48,573 | 47,778 | 38,927 | 34,561 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,369 | $6,312 | $1,648 | $350 |
| Interest Expense | $0 | $0 | $0 | $3 |
| Depreciation & Amortization | $925 | $1,221 | $1,199 | $1,330 |
| EBITDA | -$73,018 | -$122,241 | -$105,283 | -$94,069 |
| % Margin | -663.8% | – | – | -37,627.6% |